Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants
about
Tyrosine mutations within the alpha platelet-derived growth factor receptor kinase insert domain abrogate receptor-associated phosphatidylinositol-3 kinase activity without affecting mitogenic or chemotactic signal transductionDirect interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferationAbl interactor 1 binds to sos and inhibits epidermal growth factor- and v-Abl-induced activation of extracellular signal-regulated kinasesDirect association of p110 beta phosphatidylinositol 3-kinase with p85 is mediated by an N-terminal fragment of p110 betaCloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85Depletion of Pleckstrin homology domain leucine-rich repeat protein phosphatases 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoformsNuclear PI3K signaling in cell growth and tumorigenesisCRKL binding to BCR-ABL and BCR-ABL transformationTransforming pathways activated by the v-Abl tyrosine kinaseThe catalytic subunit of phosphatidylinositol 3-kinase is a substrate for the activated platelet-derived growth factor receptor, but not for middle-T antigen-pp60c-src complexesProgressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesisInteractions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.Molecular requirements for rapid plasmacytoma and pre-B lymphoma induction by Abelson murine leukemia virus in myc-transgenic mice.The v-Src SH3 domain binds phosphatidylinositol 3'-kinase.Hormone-conditional transformation by fusion proteins of c-Abl and its transforming variantsInteraction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptorsSignaling pathways activated by oncogenic forms of Abl tyrosine kinase.Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells.Oncogenic v-Abl tyrosine kinase can inhibit or stimulate growth, depending on the cell context.Mechanisms of transformation by the BCR/ABL oncogene.Natural biology of polyomavirus middle T antigen.Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.Studying the pathogenesis of BCR-ABL+ leukemia in mice.FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells.Phosphoinositide 3-kinase lipid products regulate ATP-dependent transport by sister of P-glycoprotein and multidrug resistance associated protein 2 in bile canalicular membrane vesiclesPhosphatidylinositol 3-kinase activation is mediated by high-affinity interactions between distinct domains within the p110 and p85 subunits.A tightly associated serine/threonine protein kinase regulates phosphoinositide 3-kinase activity.Transformation-defective mutants of polyomavirus middle T antigen associate with phosphatidylinositol 3-kinase (PI 3-kinase) but are unable to maintain wild-type levels of PI 3-kinase products in intact cellsOncogenic activation of c-ABL by mutation within its last exon.c-Abl-dependent molecular circuitry involving Smad5 and phosphatidylinositol 3-kinase regulates bone morphogenetic protein-2-induced osteogenesis.Lymphoid cells transformed by Abelson virus require the v-abl protein-tyrosine kinase only during early G1.Activation of phosphatidylinositol 3-kinase by epidermal growth factor, basic fibroblast growth factor, and nerve growth factor in PC12 pheochromocytoma cells.Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.Signaling networks associated with BCR-ABL-dependent transformation.The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.Oct-1 protein promotes functional transcription complex assembly on the mouse mammary tumor virus promoter.Approaches to identify kinase dependencies in cancer signalling networks.Down-regulation of Thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression.
P2860
Q24303984-ECB4BD3F-6DB0-4777-9FC0-335A6759B52FQ24522820-F046A2F0-91D6-451D-B120-0B8D9F5C7064Q24551183-221DC072-37E7-4630-83D1-601302068B43Q24613360-B05F0E42-DE18-483E-AB9C-B59CC19FFEEAQ24629213-DD3F1152-E841-41EA-B967-149E48B0433FQ24658292-875CCBDD-AA88-4E46-AC58-5AF4A37424B5Q26859127-862FA5B8-252B-404A-9FDD-8B1A7F45524EQ28140785-AE152BF6-A063-44D1-8F4F-62E88311078CQ28217156-74DDB031-B8F4-4BB1-9003-F3D7080FD2EDQ28367583-307F29B2-1E0C-4338-920B-0003391F2A7FQ30168802-3820D3E1-2C61-4E59-9B73-556508CE5ADEQ30175784-9BDAB83F-482C-44E3-A42F-0D4117697460Q30176501-B179BD5C-7292-448B-8138-2FE186C48342Q30194222-13665AA9-AEF1-46C7-9885-D5D616F5EE32Q30194840-F5A5A986-6D18-43DA-A6EC-1156D97634A0Q30194953-30AC6F1D-CC87-4414-88DE-FCA149963E38Q31169174-97C4617B-3591-4CB7-8A33-7C62346D7CF9Q33663180-2BE06362-E9A4-457B-9069-4E68064431FDQ33784347-ECD46389-D277-45B8-AC48-6529CF12F6E3Q33938463-E146443C-7A9C-4BC3-8352-78473A15BCDBQ33946147-39EF6312-785E-4400-89AD-EEA57F00272CQ33948870-6ECC497A-2E51-412D-9245-D1094BA9D18DQ34250223-2A82AB38-6FB0-4490-8C65-D234D151A42DQ35022543-F4D20E4D-80C4-4BC2-821A-D88626ED5C31Q36334327-9B466CBD-4E1C-4B10-B7A1-86B7E35FCE35Q36371049-DB841071-3609-4BDA-B4A8-FE8316E63EEDQ36371975-4458185B-CF6D-4F0B-B657-25180221CB5BQ36642568-A57C05AE-4AC9-48C2-B891-4AF8B08C3E04Q36676193-13B01D34-CB37-4506-9A9E-C8E86A74B2E7Q36693102-ADB38E83-6313-4C8C-8353-73E1B66DDEF8Q36695729-A8A00BD0-DC44-4DBD-B127-D5B0DE62694EQ37112666-7B0A4874-48C4-4FA8-A6F1-0C42DF10885EQ37116467-B2F9B191-AE7C-4ED8-8368-A53A0566F8D7Q37223924-564B4D0D-F519-4D93-A91E-AC0D8E559082Q37390575-8AF09E62-9C10-4A96-9FDB-09BF71315888Q37428655-66910FAA-1E1D-4CEF-A78F-96B27BE8EE52Q37454384-DA5FB664-4CE4-4495-A358-78AC2E3791F5Q38289112-81EB0FF9-46BA-4B8B-BAF3-94AEFD67846AQ38660465-6BA7805F-6B54-4AF9-8A2E-78066861A4C9Q39576698-2603B47A-3869-4A70-AD63-3EB03D7817B1
P2860
Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants
@ast
Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants
@en
type
label
Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants
@ast
Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants
@en
prefLabel
Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants
@ast
Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants
@en
P2093
P2860
P356
P1476
Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants
@en
P2093
D Baltimore
L C Cantley
L Varticovski
P2860
P304
P356
10.1128/MCB.11.2.1107
P407
P577
1991-02-01T00:00:00Z